Advances in Radiation Therapy for Hematologic Malignancies in the COVID-19 Era

Strategic Insights -

In response to the COVID-19 pandemic, guidelines for hypofractionated radiation therapy (hRT) regimens were published to minimize patient exposure, ensure staff safety, and conserve healthcare resources. Research conducted by the University of Texas MD Anderson Cancer Center in collaboration with the International Lymphoma Radiation Oncology Group (ILROG) aimed to evaluate the efficacy and toxicity of hRT in treating patients with hematologic malignancies during the pandemic.

Key Takeaways:

  • A retrospective multinational, multicenter study was conducted involving 219 patients from 8 different institutions treated with 255 RT courses.
  • The median RT dose was 12 Gy (range 4-39) in a median of 3 fractions (range 1-13), and the median follow-up was 232 days, with 151 patients (69%) alive at last follow-up.
  • Response within the RT field was assessed in 210 sites, and 127 sites (60%) had a confirmed complete response.
  • Maximal toxicities reported were Grade 1 (n = 48), Grade 2 (n = 25), Grade 3 (n = 3), and Grade 4 (n = 1), with Grade 3/4 toxicities including dermatitis, pain, and hematologic toxicity.
  • The study concluded that treatment of hematologic malignancies patients with hRT was generally well-tolerated, with few unexpected toxicities.
  • The research provides guidance for emergencies and suggests that hRT may be useful and could be considered even in routine settings, especially for certain patient subgroups.

Statistics:

  • 219 patients were included in the study from 8 different institutions.
  • 255 RT courses were administered to these patients.
  • 151 patients (69%) were alive at last follow-up.
  • 127 sites (60%) had a confirmed complete response.
  • 1 patient experienced Grade 4 toxicity.
  • 3 patients experienced Grade 3 toxicity.

Sources:

  • Radiotherapy and Oncology, 2025:111200
  • Elsevier Ireland Ltd
  • NewsRx, October 26, 2025